Research Topics
| B M RavinaSummaryAffiliation: National Institutes of Health Country: USA Publications
| Collaborators
|
Detail Information
Publications
Funding evidence: the National Institute of Neurological Disorders and Stroke Clinical Trials ProgramBernard Ravina
National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, USA
NeuroRx 1:317-22. 2004....- Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover studyB Ravina
NINDS, Neuroscience Center Rm 2225, 6001 Executive Blvd, Rockville, MD 20892 9257, USA
J Neurol Neurosurg Psychiatry 76:934-9. 2005..To study the safety and efficacy of a cholinesterase inhibitor, donepezil hydrochloride, for the treatment of dementia in Parkinson's disease (PD)... - The role of radiotracer imaging in Parkinson diseaseB Ravina
National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA
Neurology 64:208-15. 2005..Mechanistic information added by RTI to clinical trials may be difficult to interpret because of uncertainty about the interaction between the interventions and the tracer... - Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessmentB M Ravina
National Institute of Neurological Disorders and Stroke, National Institutes of Health, Rockville, MD 20892 9257, USA
Neurology 60:1234-40. 2003..However, there have been relatively few clinical trials aimed at demonstrating neuroprotection. The authors sought to identify potential neuroprotective agents for testing in clinical trials... - SNCA multiplication is not a common cause of Parkinson disease or dementia with Lewy bodiesJ Johnson
Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD 20892, USA
Neurology 63:554-6. 2004..The authors did not identify any subjects with multiplication of SNCA and conclude this mutation is a rare cause of disease... - Why hasn't neuroprotection worked in Parkinson's disease?Karl Kieburtz
University of Rochester Medical Center, Rochester, NY, USA
Nat Clin Pract Neurol 3:240-1. 2007 - Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxiaNicholas A Di Prospero
Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892 3705, USA
Arch Neurol 64:803-8. 2007..Some studies suggest that higher doses of idebenone may be more effective, but pharmacology and toxicology at higher doses have not been investigated in human beings... - Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trialsPaulo Guimaraes
Dept of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, 135 Cannon St Suite 303, Charleston, SC 29425, USA
Clin Trials 2:509-18. 2005..Models can help better understand behavior of the UPDRS after initiation of symptomatic therapy when scores will improve and eventually start deteriorating again... - A randomized study of the bioavailability of different formulations of coenzyme Q(10) (ubiquinone)Radu Constantinescu
Department of Neurology, Clinical Trials Coordination Center, University of Rochester Medical Center, Rochester, New York, USA
J Clin Pharmacol 47:1580-6. 2007 - Randomized, placebo-controlled, parallel group versus crossover study designs for the study of dementia in Parkinson's diseaseMary E Putt
Department of Clinical Epidemiology and Biostatistics, School of Medicine, University of Pennsylvania, 621 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104 6021, USA
Control Clin Trials 23:111-26. 2002..4 months, respectively, a substantial saving over either parallel group design. The cost of allowing for carryover in the sample size calculation is about 1.2 months of study time... - Neuroprotection in Parkinson's disease: an elusive goalKevin M Biglan
Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14620, USA
Semin Neurol 27:106-12. 2007..Ultimately, overcoming the unique challenges of a heterogenous, slowly progressive disorder with multiple potential outcome measures will be necessary to identify treatments that have meaningful effects... - A responsive outcome for Parkinson's disease neuroprotection futility studiesJordan J Elm
Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, SC 29425, USA
Ann Neurol 57:197-203. 2005.... - Exercise-induced dystonia as a preceding symptom of familial Parkinson's diseaseMichiko K Bruno
Parkinson s Unit, Division of Neurogenetics, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA
Mov Disord 19:228-30. 2004..Further genotype-phenotype studies in this and similar families may give clues to pre-symptomatic symptoms in PD and may reflect a particular phenotype of interest for genetics studies in the future... - Brain banking for neurodegenerative diseasesDiane D Murphy
National Institute of Neurological Disorders and Stroke, NIH, MD 20852, USA
Curr Opin Neurol 16:459-63. 2003..The pathological substrates are then studied for their role in how they cause dysfunction in disease, or how their accumulation is presumably damaging... - From chemical to drug: neurodegeneration drug screening and the ethics of clinical trialsJill Heemskerk
Technology Development Program, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland 20892, USA
Nat Neurosci 5:1027-9. 2002 - The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson's diseaseDavid J Gill
Department of Neurology, University of Rochester, Rochester, NY, USA
Mov Disord 23:1043-6. 2008..81. The correlation coefficient between the MoCA and a neuropsychologic battery was 0.72. The MoCA is reliable and valid in the PD population and warrants further study as a screening tool for cognitive dysfunction... - Bilateral stimulation of the subthalamic nucleus in patients with Parkinson disease: a study of efficacy and safetyTanya Simuni
Parkinson's Disease and Movement Disorders Center, Pennsylvania Hospital, Philadelphia, USA
J Neurosurg 96:666-72. 2002..Serious adverse events were common in this cohort; however, only two patients suffered permanent sequelae... - Preference-based quality-of-life in patients with Parkinson's diseaseAndrew Siderowf
Departments of Neurology, University of Pennsylvania School of Medicine, Philadelphia, USA
Neurology 59:103-8. 2002..Because of this property, they are the appropriate measures of quality of life for cost-effectiveness analysis. Although preference-based scales are widely used, their validity has rarely been tested in specific patient groups... - Mutation at the SCA17 locus is not a common cause of parkinsonismDena Hernandez
Molecular Genetics Section, National Institute on Aging, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
Parkinsonism Relat Disord 9:317-20. 2003..We did not find any repeat sizes in the pathogenic range. The repeats we observed ranged from 29 to 41 (mean 36.8; median 37). We conclude that SCA-17 repeat expansion mutations are not a common cause of familial parkinsonism... - Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work groupBernard Ravina
Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14620, USA
Mov Disord 22:1061-8. 2007..These criteria require validation and may be refined, but form a starting point for studies of the epidemiology and pathophysiology of PDPsy, and are a potential indication for therapy development... - Widespread decrease of nicotinic acetylcholine receptors in Parkinson's diseaseMasahiro Fujita
Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Building 1, Room B3 10, I Center Drive, MSC 0135, Bethesda, MD, USA
Ann Neurol 59:174-7. 2006..Nicotinic acetylcholine receptors have close interactions with the dopaminergic system and play critical roles in cognitive function. The purpose of this study was to compare these receptors between living PD patients and healthy subjects... - Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work GroupLaura Marsh
Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
Mov Disord 21:148-58. 2006..The proposed diagnostic criteria are provisional and intended to be defined further and validated but provide a common starting point for clinical research in PD-associated depression... - Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutationStephen Hague
Molecular Genetics Section, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA
Ann Neurol 54:271-4. 2003..This subject was diagnosed with probable PD at age 24 years with asymmetric onset and an excellent response to levodopa therapy. Our observations suggest that sequence alterations in DJ-1 are a rare cause of early-onset PD... - Neuroprotection in Parkinson's disease: myth or reality?Tiffini Voss
Department of Neurology, University of Rochester School of Medicine and Dentistry, Movement and Inherited Neurological Disorders Unit, Rochester, NY 14620, USA
Curr Neurol Neurosci Rep 8:304-9. 2008..It is hoped that ongoing work in this field will lead to treatments that delay the progression of PD...